Life Sciences Transformational R&D Investment Fund (TRIF) Pilot
The Life Sciences Transformational R&D Investment Fund Pilot is a newly established £50 million capital grant opportunity. It aims to boost research and development (R&D) within the UK's Life Sciences sector by supporting large-scale investments focused on innovation and strengthening health resilience. The fund priori
- Funding
- See official notice
- Deadline
- April 1, 2028
- Status
- OPEN
- Category
- Research & Science
- Opens
- September 26, 2025
- Directory link check
- October 24, 2026
About this opportunity
The Life Sciences Transformational R&D Investment Fund Pilot is a newly established £50 million capital grant opportunity. It aims to boost research and development (R&D) within the UK's Life Sciences sector by supporting large-scale investments focused on innovation and strengthening health resilience. The fund prioritises projects with the potential to generate economic benefits. This is a new fund that works alongside the separate Life Sciences Innovative Manufacturing Fund (LSIMF). Projects with a total cost (including capital expenditure) of at least £100 million are eligible to apply. The grant awarded is set at the minimum level necessary to ensure your project proceeds while adhering to UK subsidy regulations, typically ranging from 10-20% of total project costs. For instance, a project with a total cost of £100 million would generally receive a grant of £10-20 million.
Eligibility recorded
Your Company To be considered eligible for the TRIF Pilot, your company must meet the following requirements: Be a UK-registered and wholly private sector business. Operate as a product developer , contract development and manufacturing organisation (CDMO) , or generics manufacturer . Provide two years of audited accounts for the applicant company or parent entity. If unavailable, you must demonstrate that the remaining project funding has been secured. Show a track record of successfully developing or manufacturing medicines or medical devices, either in the UK or internationally. Your Project To be eligible for the fund, your R&D project must: Have a total cost (including eligible capital and non-capital costs) of at least £100m . Be located in the UK . Be primarily a capital investment . Be a single company investment (as opposed to forming a partnership between companies or other types of organisations) Be dependent on the grant to proceed. Projects that would otherwise not occur, be delayed (by three years or more), scaled down, or relocated overseas without the grant may be eligible. R&D Focus Areas Applications are invited to support projects that are engaged in R&D activities within the following key areas: · Human Medicines : This includes projects that focus on the development and innovation of pharmaceuticals, encompassing both active pharmaceutical ingredients (APIs) and finished drug products intended for human use. · Medical Diagnostics : Projects aimed at advancing tools, systems, or methods for the identification and monitoring of diseases. This area covers the R&D of diagnostic technologies that support timely and accurate disease detection. · MedTech Products : This covers the creation and enhancement of medical devices specifically related to human health. Eligible projects may involve the design, testing, or improvement of medical devices. Ineligible Projects: Projects relating to the following are not eligible for funding from the TRIF Pilot: Veterinary medicines Herbal medicines Nutritional supplements or vitamins Raw ingredients (e.g solvents, buffers and cleaning agents) The production of single-use consumables that are not integrated into a larger product (e.g manufacturing syringes independently from diagnostic kits) Secondary packaging for products or materials (e.g package inserts, labelling and boxes)
Recorded geography: United Kingdom
Directory verification note
Automatically synchronized from UK Find a Grant. Source identifier: life-sciences-transformational-rd-investment-fund-trif-pilot-1. Confirm details on the official page.